SEC Company Response from AIM ImmunoTech Inc. (AIM) (CIK 0000946644) (AIM) — Jul 20, 2018
AIM ImmunoTech Inc. (AIM) (CIK 0000946644)
Date: July 20, 2018 · CIK: 0000946644 · Accession: 0001493152-18-010281
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226057
Letter
Division of Corporation Finance Office of Healthcare & Insurance Securities and Exchange Commission Re: Hemispherx Biopharma, Inc. Registration Statement on Form S-1 Filed July 2, 2018 File No. 333-226057
Dear Ms. Paik:
On behalf of Hemispherx Biopharma, Inc. (the “Company”), I hereby file Amendment No. 1 (the “Amendment”) to the above referenced registration statement (the “Registration Statement”) and respond to the comments contained in the Commission’s July 11, 2018 comment letter.
Registration Statement on Form S-1 filed July 2, 2018
General
Comment No. 1: We note that you entered into an amended and restated Rights Agreement on November 14, 2017. Please revise your fee table to register the Rights to Purchase Series A Junior Participating Preferred Stock as separate securities. In addition, please include a description of the Rights to Purchase Series A Junior Participating Preferred Stock in the prospectus or incorporate by reference the description of the Rights to Purchase Series A Junior Participating Preferred Stock contained in the Form 8-A filed November 14, 2017, pursuant to Item 9 of Form S-1.
Response: In the Amendment, the fee table has been revised to register the Rights to Purchase Series A Junior Participating Preferred Stock (the “Rights”) and descriptions of the Rights and the corresponding Rights Plan have been added and incorporated by reference from the Form 8-A filed November 14, 2017.
If you have any additional questions or comments, please contact me. If not, the Company will file an acceleration request.
Very
truly yours,
/s/
Richard Feiner
Show Raw Text
CORRESP
1
filename1.htm
SILVERMAN
SHIN & BYRNE PLLC
Wall
Street Plaza
22nd
Floor
88
Pine Street
NEW
YORK, NY 10005
212.779.8600
Facsimile:
212.779.8858
E-mail:
Rfeiner@Silverfirm.com
__________
New
Jersey
19
Engle Street
Tenafly,
NJ 07670
(201)
567-4969
July
20, 2018
Division
of Corporation Finance
Office
of Healthcare & Insurance
Securities
and Exchange Commission
100
F Street, NE
Washington,
DC 20549
Attn:
Irene Paik, Esq.
Re:
Hemispherx
Biopharma, Inc.
Registration
Statement on Form S-1
Filed
July 2, 2018
File
No. 333-226057
Dear
Ms. Paik:
On
behalf of Hemispherx Biopharma, Inc. (the “Company”), I hereby file Amendment No. 1 (the “Amendment”)
to the above referenced registration statement (the “Registration Statement”) and respond to the comments contained
in the Commission’s July 11, 2018 comment letter.
Registration
Statement on Form S-1 filed July 2, 2018
General
Comment
No. 1: We note that you entered into an amended and restated Rights Agreement on November 14, 2017. Please revise your
fee table to register the Rights to Purchase Series A Junior Participating Preferred Stock as separate securities. In
addition, please include a description of the Rights to Purchase Series A Junior Participating Preferred Stock in the
prospectus or incorporate by reference the description of the Rights to Purchase Series A Junior Participating Preferred
Stock contained in the Form 8-A filed November 14, 2017, pursuant to Item 9 of Form S-1.
Response:
In the Amendment, the fee table has been revised to register the Rights to Purchase Series A Junior Participating Preferred
Stock (the “Rights”) and descriptions of the Rights and the corresponding Rights Plan have been added and
incorporated by reference from the Form 8-A filed November 14, 2017.
If
you have any additional questions or comments, please contact me. If not, the Company will file an acceleration request.
Very
truly yours,
/s/
Richard Feiner
Richard
Feiner
cc:
Adam Pascale